Reply to letter in response to Rethinking the diagnosis of double‐seronegative myasthenia gravis.
Saved in:
| Title: | Reply to letter in response to Rethinking the diagnosis of double‐seronegative myasthenia gravis. |
|---|---|
| Authors: | Martinez‐Harms, Rodrigo (AUTHOR), Barnett, Carolina (AUTHOR), Alcantara, Monica (AUTHOR), Bril, Vera (AUTHOR) |
| Source: | European Journal of Neurology. Mar2024, Vol. 31 Issue 3, p1-2. 2p. |
| Subjects: | Myasthenia gravis, Pathology, Diagnosis, Nicotinic acetylcholine receptors |
| Abstract: | This document is a reply to a letter in response to a previously published article titled "Clinical Characteristics and Treatment Outcomes in Patients with Double-Seronegative Myasthenia Gravis." The authors of the reply express gratitude for the comments and acknowledge the importance of further discussion on the topic of patients without detectable antibodies to nicotinic acetylcholine receptor (AChR) and muscle-specific kinase. They agree with the suggestion that electrophysiological findings and complementary diagnostic tests should be considered in the diagnosis of myasthenia gravis (MG). The authors also highlight the need for further characterization of serological markers in seronegative MG patients and the potential role of novel antibodies in the disease. They conclude that dSNMG patients show significant clinical improvement after treatment, supporting an immune-mediated pathophysiology, and emphasize the importance of developing new biomarkers for personalized clinical characterization and individualized therapeutic approaches. [Extracted from the article] |
| Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | This document is a reply to a letter in response to a previously published article titled "Clinical Characteristics and Treatment Outcomes in Patients with Double-Seronegative Myasthenia Gravis." The authors of the reply express gratitude for the comments and acknowledge the importance of further discussion on the topic of patients without detectable antibodies to nicotinic acetylcholine receptor (AChR) and muscle-specific kinase. They agree with the suggestion that electrophysiological findings and complementary diagnostic tests should be considered in the diagnosis of myasthenia gravis (MG). The authors also highlight the need for further characterization of serological markers in seronegative MG patients and the potential role of novel antibodies in the disease. They conclude that dSNMG patients show significant clinical improvement after treatment, supporting an immune-mediated pathophysiology, and emphasize the importance of developing new biomarkers for personalized clinical characterization and individualized therapeutic approaches. [Extracted from the article] |
|---|---|
| ISSN: | 13515101 |
| DOI: | 10.1111/ene.16152 |
